Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 1.51% is 68% below its 5-year average of 4.65%, around the middle of its 5-year range (-8.06%–17.86%).
88.98% below its 12-month average of 13.71%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01%.
RETURN ON ASSETS (ROA)
1.51%
RETURN ON ASSETS (ROA) AVG TTM
13.71%
RETURN ON ASSETS (ROA) AVG 3Y
9.00%
RETURN ON ASSETS (ROA) AVG 5Y
4.65%
RETURN ON ASSETS (ROA) AVG 10Y
-2.15%
RETURN ON ASSETS (ROA) AVG 15Y
-3.37%
RETURN ON ASSETS (ROA) AVG 20Y
-1.28%
CURRENT VS TTM AVG
-88.98%
CURRENT VS 3Y AVG
-83.22%
CURRENT VS 5Y AVG
-67.56%
CURRENT VS 10Y AVG
+170.11%
CURRENT VS 15Y AVG
+144.77%
CURRENT VS 20Y AVG
+218.31%
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+106.05%
vs the sector median at left
Alkermes plc
Market Cap
$7.17B
Return on Assets (ROA)
1.51%
TTM Avg
13.71%
3Y Avg
9.00%
5Y Avg
4.65%
Market Cap
$6.86B
Return on Assets (ROA)
-63.13%
TTM Avg
-53.05%
3Y Avg
-49.25%
5Y Avg
-42.24%
Market Cap
$7.61B
Return on Assets (ROA)
13.18%
TTM Avg
-36.35%
3Y Avg
-30.02%
5Y Avg
-30.02%
Market Cap
$7.65B
Return on Assets (ROA)
7.23%
TTM Avg
4.54%
3Y Avg
2.50%
5Y Avg
1.48%
Market Cap
$6.68B
Return on Assets (ROA)
17.41%
TTM Avg
17.14%
3Y Avg
16.98%
5Y Avg
18.36%
Market Cap
$6.62B
Return on Assets (ROA)
-3.91%
TTM Avg
11.88%
3Y Avg
0.12%
5Y Avg
-6.73%
Market Cap
$6.61B
Return on Assets (ROA)
-13.77%
TTM Avg
-40.95%
3Y Avg
-52.61%
5Y Avg
-44.58%
Market Cap
$7.80B
Return on Assets (ROA)
-46.45%
TTM Avg
-48.58%
3Y Avg
-49.83%
5Y Avg
-41.46%
Market Cap
$6.50B
Return on Assets (ROA)
4.17%
TTM Avg
-0.69%
3Y Avg
-1.80%
5Y Avg
-0.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alkermes plc (ALKS) | $7.17B | 1.51% | 13.71% | 9.00% | 4.65% |
| Immunovant, Inc. (IMVT)vs › | $6.86B | -63.13% | -53.05% | -49.25% | -42.24% |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 13.18% | -36.35% | -30.02% | -30.02% |
| HealthEquity, Inc. (HQY)vs › | $7.65B | 7.23% | 4.54% | 2.50% | 1.48% |
| Chemed Corporation (CHE)vs › | $6.68B | 17.41% | 17.14% | 16.98% | 18.36% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.62B | -3.91% | 11.88% | 0.12% | -6.73% |
| GRAIL Inc. (GRAL)vs › | $6.61B | -13.77% | -40.95% | -52.61% | -44.58% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.80B | -46.45% | -48.58% | -49.83% | -41.46% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.50B | 4.17% | -0.69% | -1.80% | -0.78% |
| CG Oncology Inc. (CGON)vs › | $6.06B | -20.67% | -16.00% | -20.09% | -20.45% |
ROA
1.5%
ROE
3.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 9.55% |
| 2024-12-31 | 17.86% |
| 2023-12-31 | 16.65% |
| 2022-12-31 | -8.06% |
| 2021-12-31 | -2.38% |
| 2020-12-31 | -5.69% |
| 2019-12-31 | -10.89% |
| 2018-12-31 | -7.63% |
| 2017-12-31 | -8.79% |
| 2016-12-31 | -12.07% |
| 2015-12-31 | -12.24% |
| 2014-12-31 | -1.56% |
| 2013-03-31 | 1.70% |
| 2012-03-31 | 1.74% |
| 2011-03-31 | -7.55% |
| 2010-03-31 | -8.83% |
| 2009-03-31 | -7.62% |
| 2008-03-31 | 19.88% |
| 2007-03-31 | 22.86% |
| 2006-03-31 | 1.68% |
| 2005-03-31 | 1.13% |
| 2004-03-31 | -37.25% |
| 2003-03-31 | -34.51% |
| 2002-03-31 | -36.72% |
| 2001-03-31 | -15.88% |
| 2000-03-31 | -4.18% |
| 1999-03-31 | -31.94% |
| 1998-03-31 | -18.64% |
| 1997-03-31 | -12.02% |
| 1996-03-31 | -32.63% |
